Tina E. Hulse
11 IP cases indexed. Covers patent matters.
Cases Presided Over
11 cases indexed | Page 1 of 1
Neurocrine Biosciences, Inc. v.Spruce Biosciences, Inc.
The PTAB held that Neurocrine Biosciences’ challenge to Spruce Biosciences’ ’201 patent succeeded; all 19 claims were found unpatentable for lack of written description under §112(a).
Neurocrine Biosciences, Inc. v.Spruce Biosciences, Inc.
The PTAB held that Neurocrine Biosciences' challenge succeeded; claims 1‑25 of Spruce Biosciences' ’908 patent were found unpatentable for lack of written description under 35 U.S.C. §112(a). The Board applied Ariad standards and rejected the genus claim.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB held that most of Guardant Health’s ’822 patent claims are obvious over prior‑art sequencing methods, cancelling claims 1‑11, 13, and 17‑20, while claim 12 remains patentable.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB affirmed Guardant Health's U.S. Patent 11,149,306 covering cell‑free DNA tagging and counting, finding none of the 29 challenged claims unpatentable after Tempus AI's IPR challenge.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB instituted an inter partes review of Guardant Health’s cfDNA sequencing patent after Foundation Medicine (Petitioner) showed a reasonable likelihood of success on an obviousness ground over several prior‑art references.
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy, Inc. successfully petitioned the PTAB to institute an IPR against Exact Sciences Corporation's patent (11634781). The Board found a reasonable likelihood of prevailing on all grounds, specifically regarding obviousness under 35 U.S.C. § 103.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB granted a settlement‑based termination for Jeisys Medical in three IPRs while allowing the proceedings to continue for EndyMed. The settlement agreement was ordered to be kept confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB instituted an IPR in a colorectal cancer screening case, finding a reasonable likelihood that Geneoscopy's challenged claims are unpatentable. The Board accepted the petitioner's argument that combinations of various prior art references teach every limitation of the claims with a reason for combination.
Jeisys Medical Inc. et al. v.Serendia, LLC
The Board granted a joint motion to terminate the IPR only for Jeisys Medical Inc. after a settlement with Serendia, while EndyMed remains as a petitioner. The settlement agreement was ordered confidential.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The Board granted a joint motion to terminate the IPR as to Jeisys Medical Inc. following a settlement with Serendia, while allowing EndyMed petitioners to continue the review.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.